Haemonetics (HAE) Competitors

Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Do analysts rate HAE or DXCM?

Haemonetics presently has a consensus target price of $97.30, suggesting a potential upside of 32.26%. DexCom has a consensus target price of $99.60, suggesting a potential upside of 18.43%. Given Haemonetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Haemonetics is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
DexCom	0 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.91

Does the media favor HAE or DXCM?

In the previous week, DexCom had 2 more articles in the media than Haemonetics. MarketBeat recorded 17 mentions for DexCom and 15 mentions for Haemonetics. DexCom's average media sentiment score of 1.36 beat Haemonetics' score of 0.43 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	12 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is HAE or DXCM more profitable?

DexCom has a net margin of 12.90% compared to Haemonetics' net margin of 12.32%. DexCom's return on equity of 30.05% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	12.32%	26.37%	9.22%
DexCom	12.90%	30.05%	10.00%

Which has stronger valuation & earnings, HAE or DXCM?

DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36B	2.60	$167.68M	$3.31	22.23
DexCom	$4.03B	8.18	$576.20M	$1.34	62.76

Do insiders & institutionals hold more shares of HAE or DXCM?

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, HAE or DXCM?

Haemonetics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Summary

DexCom beats Haemonetics on 11 of the 16 factors compared between the two stocks.